Talon Therapeutics, Inc. Reports Fourth Quarter and Year End 2011 Financial Results
29 mars 2012 09h00 HE
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., March 29, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the fourth quarter and year ended December 31, 2011, and provided a...
Talon Therapeutics to Host a Conference Call to Report 2011 Financial Results and Business Update on March 29, 2012
26 mars 2012 20h23 HE
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., March 26, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Thursday, March 29, 2012 at 10:00AM PDT, to discuss fourth quarter and full...
Talon Therapeutics' Product Candidate Marqibo(R) Receives a Positive Vote From the Oncologic Drugs Advisory Committee (ODAC)
21 mars 2012 13h18 HE
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., March 21, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), announced the Oncologic Drugs Advisory Committee voted 7 yes, 4 no, and 2 abstain that evidence from...
Talon Therapeutics to Host a Conference Call on March 22, 2012 to Discuss the Results of the ODAC Meeting on Marqibo(R)
20 mars 2012 20h13 HE
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., March 20, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Thursday, March 22, 2012 at 9:00AM PT, to discuss the outcome of the...
Talon Therapeutics' Product Candidate Marqibo(R) to be Assessed by Oncologic Drug Advisory Committee (ODAC) on March 21, 2012 With a PDUFA Date of May 13, 2012
03 févr. 2012 10h49 HE
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., Feb. 3, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc. (OTCBB:TLON) announced Marqibo® (vincristine sulfate liposomes injection) is scheduled to be assessed by ODAC on...
Talon Therapeutics Announces $11M Financing
09 janv. 2012 12h43 HE
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc., (OTCBB:TLON), today announced that it has entered into an Investment Agreement with Warburg Pincus and Deerfield...
Talon Therapeutics Announces First Patient Enrolled in the Phase 3 OPTIMAL>60 Study of Marqibo(R) in Adult Patients With Newly Diagnosed, Aggressive Non-Hodgkin's Lymphoma
29 nov. 2011 09h00 HE
|
Talon Therapeutics, Inc.
Conducted by the prestigious German High-Grade NHL Study Group
R-CHMP-14 (M=Marqibo) versus R-CHOP-14 (O=standard vincristine)
Powered to demonstrate superior progression-free survival of...
Talon Therapeutics, Inc. Reports Third Quarter 2011 Financial Results
14 nov. 2011 17h00 HE
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and nine months ended September 30, 2011.
"In the third...
Talon Therapeutics to Host a Conference Call to Report Third Quarter 2011 Financial Results and Business Update on November 15, 2011
11 nov. 2011 16h21 HE
|
Talon Therapeutics, Inc.
SAN MATEO, Calif., Nov. 11, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Tuesday, November 15, 2011 at 9:00AM PT, to include a discussion of financial...
Talon Therapeutics' New Drug Application for Marqibo(R) Accepted for Filing by the United States Food and Drug Administration
27 sept. 2011 09h00 HE
|
Talon Therapeutics, Inc.
Accelerated approval review path confirmed by the FDA
Prescription Drug User Fee Act (PDUFA) date set for May 13, 2012
SAN MATEO, Calif., Sept. 27, 2011 (GLOBE NEWSWIRE) -- Talon...